Alzinova AB presents preclinical data on the Company's substances at the AAIC conference
Alzinova AB today presented data on the monoclonal antibody ALZ-201 at the Alzheimer’s Association International Conference (AAIC), which is held as a virtual event this year due to the coronavirus. The preclinical data support the continued development of the Company's lead candidate, ALZ-101.Dr. Anders Sandberg, Chief Scientific Officer, today presented the poster titled: Specific targeting of a highly toxic subpopulation of Aβ42 oligomers for the treatment of Alzheimer’s disease. The poster provides an overview of the Company's research strategy and data demonstrating that the